Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 44Pancreatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 37Triple Negative Breast Neoplasms 28Ovarian Neoplasms 20Fallopian Tube Neoplasms 19Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasm Metastasis 11Uterine Cervical Neoplasms 8Melanoma 7Inflammatory Breast Neoplasms 7Breast Neoplasms, Male 6Stomach Neoplasms 5Esophageal Squamous Cell Carcinoma 5Cholangiocarcinoma 5Brenner Tumor 5Pancreatic Adenocarcinoma 4Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Endometrial Neoplasms 3

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × Taxes × Clear all
NCT02581982 2023-01-10

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Wake Forest University Health Sciences

Phase 2 Completed
27 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03464734 2022-11-30

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed
70 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT04730219 2022-11-30

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

Tianjin Medical University Second Hospital

Phase 2 Unknown
48 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT03051373 2021-08-09

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Chinese PLA General Hospital

Phase 2 Completed
108 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡